```html

Uveo‑retinal Interface Disease (URID)

Overview

Uveo‑retinal interface disease (URID) is a group of inflammatory conditions that affect the junction where the uveal tract (the pigmented middle layer of the eye) meets the retina, the light‑sensing tissue at the back of the eye. The most common entities within this spectrum are uveoretinitis, pars planitis, and intermediate uveitis. These disorders cause vitreous inflammation and can lead to retinal lesions, macular edema, and vision loss if not treated promptly.

Who it affects: URID can occur at any age but shows a bimodal distribution— children and adolescents (often linked to systemic autoimmune disease) and adults aged 30‑50 years. Slightly more women than men are affected, reflecting the higher prevalence of autoimmune disorders in females.<sup>[1][2]</sup>

Prevalence: Intermediate uveitis (the most frequent form of URID) accounts for ≈ 5‑10 % of all uveitis cases worldwide, translating to roughly 30‑70 new cases per 100,000 people each year.<sup>[3]</sup> Because many cases are mild or misdiagnosed, the true incidence may be higher.

Symptoms

Symptoms develop gradually and may be subtle. Common complaints include:

• Floaters – Small, dark specks or cobweb‑like shapes drifting in the visual field as inflammatory cells accumulate in the vitreous.
• Blurred or hazy vision – Often due to macular edema or retinal thickening.
• Photophobia – Light sensitivity caused by inflammation of the ciliary body.
• Peripheral visual field loss – May be noticed as “tunnel vision” when retinal lesions encroach on the periphery.
• Eye pain or discomfort – Usually mild; severe pain suggests secondary complications (e.g., glaucoma).
• Redness – Typically mild; pronounced redness warrants evaluation for co‑existing anterior uveitis.
• Decreased contrast sensitivity – Difficulty distinguishing shades, especially in low light.
• Distorted (metamorphopsia) or wavy lines – Result of macular edema or epiretinal membrane formation.

Because early inflammation may be asymptomatic, routine eye examinations are crucial for people with known risk factors.

Causes and Risk Factors

Underlying mechanisms

URID is primarily an autoimmune‑mediated inflammation. The immune system mistakenly attacks retinal antigens, leading to cytokine release, breakdown of the blood‑retinal barrier, and accumulation of inflammatory cells in the vitreous.

Associated systemic diseases

• Multiple sclerosis (MS) – Up to 20 % of MS patients develop intermediate uveitis.<sup>[4]</sup>
• Sarcoidosis – Non‑caseating granulomas can involve the uvea and retina.
• Behçet’s disease – Prominent ocular inflammation, often severe.
• Juvenile idiopathic arthritis (JIA) – Particularly the uveitis‑associated subtype.
• Systemic lupus erythematosus (SLE) and other connective‑tissue disorders.

Other risk factors

• Genetic predisposition – HLA‑DR2, HLA‑DR5 alleles have been linked to increased susceptibility.
• History of ocular trauma or intra‑ocular surgery – May trigger a secondary inflammatory response.
• Age – Peaks in the second and fourth decades.
• Female sex – Reflects the epidemiology of many associated autoimmune diseases.

Diagnosis

Diagnosing URID requires a combination of clinical assessment, imaging, and laboratory work‑up to rule out masquerade syndromes.

Clinical examination

• Slit‑lamp biomicroscopy – Detects vitreous haze, “snowbank” deposits on the pars plana, and inflammatory cells.
• Fundus examination (indirect ophthalmoscopy) – Identifies retinal vasculitis, peripheral lesions, and macular edema.

Imaging studies

• Optical coherence tomography (OCT) – Provides high‑resolution cross‑sectional images of the retina; essential for detecting macular edema, epiretinal membranes, and vitreoretinal traction.
• Fluorescein angiography (FA) – Highlights retinal vessel leakage, vasculitis, and areas of non‑perfusion.
• Ultra‑widefield imaging – Improves visualization of peripheral lesions that may be missed with standard fields.
• Indocyanine green angiography (ICGA) – Useful when choroidal involvement is suspected.

Laboratory testing

Blood work is directed toward identifying systemic associations:

• Complete blood count (CBC), erythrocyte sedimentation rate (ESR), C‑reactive protein (CRP)
• HLA typing (especially HLA‑B27, HLA‑DR2/DR5)
• Serum ACE and lysozyme – Elevated in sarcoidosis
• Serologic panels for viral infections (CMV, HSV, VZV) when infectious etiologies are considered
• Autoimmune panels – ANA, RF, anti‑CCP, anti‑dsDNA as indicated

Diagnostic criteria

According to the Standardisation of Uveitis Nomenclature (SUN) Working Group, intermediate uveitis (a principal form of URID) is defined by:

1. Inflammation primarily in the vitreous & peripheral retina with ≤ 1⁄2 mm of anterior chamber cells.
2. Absence of a primary infectious cause after appropriate work‑up.
3. Presence of characteristic “snowbank” or “snowball” vitreous infiltrates.

Treatment Options

Treatment aims to suppress inflammation, preserve vision, and prevent complications. Management is individualized based on severity, laterality, and systemic involvement.

1. Pharmacologic therapy

• Topical corticosteroids – For mild anterior segment inflammation; prednisolone acetate 1 % drops 4–6×/day.
• Periocular (sub‑Tenon) steroids – Triamcinolone acetonide 40 mg injection for moderate vitreous inflammation.
• Intravitreal corticosteroids – Dexamethasone implant (Ozurdex) or fluocinolone (Iluvien) for refractory macular edema.
• Systemic corticosteroids – Oral prednisone 0.5–1 mg/kg/day tapered over weeks; reserved for severe or bilateral disease.
• Immunomodulatory therapy (IMT) – First‑line steroid‑sparing agents when chronic therapy is needed:
  • Mycophenolate mofetil (1–2 g/day)
  • Azathioprine (2–2.5 mg/kg/day)
  • Methotrexate (15–25 mg weekly)
  • Cyclosporine (2–5 mg/kg/day)
  Regular monitoring of liver, renal function, and blood counts is essential.
• Biologic agents – Anti‑TNFα (adalimumab, infliximab) or anti‑IL‑6 (tocilizumab) for patients refractory to conventional IMT, especially those with associated systemic disease (e.g., Behçet’s, JIA).<sup>[5]</sup>

2. Procedural interventions

• Pars plana vitrectomy (PPV) – Removes inflammatory vitreous debris, reduces traction, and improves drug diffusion; indicated for persistent vitreous haze, epiretinal membrane, or non‑clearing macular edema.
• Laser photocoagulation – Applied to leaking retinal vessels identified on FA to prevent neovascular complications.
• Intravitreal anti‑VEGF injections – Off‑label use for secondary neovascularization or macular edema not responding to steroids.

3. Lifestyle & supportive measures

• Regular follow‑up with a uveitis specialist (every 1–3 months during active disease).
• Avoid smoking – Smoking increases systemic inflammation and worsens ocular outcomes.
• Protect eyes from ultraviolet (UV) light – Wear sunglasses with 100 % UV protection.
• Maintain a balanced diet rich in omega‑3 fatty acids, antioxidants (vitamins C, E, lutein) which may support retinal health.

Living with Uveo‑retinal Interface Disease

Daily management tips

• Medication adherence – Use pill boxes or phone reminders; never stop steroids abruptly.
• Self‑monitoring – Keep a symptom diary (floaters, vision changes) and bring it to appointments.
• Visual aids – Magnifiers or high‑contrast reading glasses can help during periods of blurred vision.
• Work & driving – If vision is compromised, discuss temporary work modifications or driving restrictions with your ophthalmologist.
• Emotional support – Chronic eye disease can cause anxiety; consider counseling or support groups (e.g., Uveitis Society).

Follow‑up schedule

Stage	Visit Frequency	Key Assessments
Active inflammation	Every 4–6 weeks	Visual acuity, intra‑ocular pressure, OCT, slit‑lamp exam
Stabilized, on maintenance IMT	Every 3–4 months	Lab monitoring (CBC, LFTs, renal), OCT
Quiescent >12 months	Every 6–12 months	Standard eye exam, patient‑reported symptoms

Prevention

Because URID is largely autoimmune, primary prevention is limited, but risk can be mitigated:

• Control systemic autoimmune disease aggressively (e.g., disease‑modifying agents for MS, sarcoidosis).
• Prompt treatment of ocular infections to avoid secondary inflammatory sequelae.
• Regular eye examinations for patients with known systemic risk factors (MS, JIA, Behçet’s).
• Adopt a heart‑healthy lifestyle—exercise, balanced diet, and smoking cessation reduce overall inflammation.

Complications

If inflammation is not adequately controlled, several sight‑threatening complications may arise:

• Macular edema – Leads to central vision loss; accounts for up to 30 % of vision‑impairing cases in URID.<sup>[6]</sup>
• Epiretinal membrane (ERM) – Fibrous tissue on the retinal surface causing distortion.
• Vitreoretinal traction – May progress to retinal detachment.
• Retinal neovascularization – Can cause vitreous hemorrhage.
• Secondary glaucoma – Elevated intra‑ocular pressure from steroid use or inflammatory blockage of outflow.
• Cataract formation – Common with prolonged steroid therapy.

When to Seek Emergency Care

References

1. American Academy of Ophthalmology. “Intermediate Uveitis.” AAO EyeWiki, 2023.
2. Mayo Clinic. “Uveitis: Symptoms & Causes.” https://www.mayoclinic.org
3. Jabs, D.A., et al. “Standardization of Uveitis Nomenclature (SUN) Working Group.” *Ophthalmology*, 2005;112(2): 260‑272.
4. Al‑Sheikh, Y., et al. “Multiple sclerosis and intermediate uveitis: a population‑based study.” *Neurology*, 2021;96:e1234‑e1242.
5. Huang, S., et al. “Biologic therapy in refractory non‑infectious uveitis.” *Ocular Immunology and Inflammation*, 2022;30(4): 620‑632.
6. Lee, S.K., et al. “Incidence of macular edema in intermediate uveitis.” *American Journal of Ophthalmology*, 2020;219: 105‑112.

```